Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of DPD activity on the efficacy of capecitabine
2024-517481-41-00Phase 2Authorised
- Sponsor
- Centre Antoine Lacassagne
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of capecitabine in breast cancer, sponsored by Centre Antoine Lacassagne. Planned start Oct 2024; status: authorised.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-517481-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517481-41-00.